Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental Research

Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental Research
warning The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05669105
Recruitment Status : **RECRUITING NOW**

First Posted : December 30, 2022

Last Update Posted : December 30, 2022

Sponsor:

Information provided by (Responsible Party):

Sanguine Biosciences

Go to 

Brief Summary:

The study objective is to collect biospecimen samples (e.g., whole blood) from participants diagnosed with active lung cancer to investigate the immune response to develop treatments and therapies.

Non Small Cell Lung Cancer Diagnostic Test: Specimen sample

Go to 

Layout table for study information
Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental Research
Actual Study Start Date : February 19, 2022
Estimated Primary Completion Date : April 2023
Estimated Study Completion Date : April 2023
Resource links provided by the National Library of Medicine NIH NLM ABRV BLK 4

Go to 

Intervention Details:

Go to 

Primary Outcome Measures :

  1. Biospecimen & Clinical Data Collection [ Time Frame: 10 years ]

    Collecting biospecimen samples (e.g., whole blood) from participants diagnosed with various active lung cancers so that investigations into the immune response can take place and aid in understanding active lung cancer biomarkers for future early diagnosis and treatment options.

Go to 

Information from the National Library of Medicine NIH NLM ABRV BLK 4

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample

The study will enroll up to 200 participants. Recruitment will occur through Sanguine advertisements, partnerships with cancer foundations, and cancer centers. Participants may be contacted for future studies.

Inclusion Criteria:

  • Participants willing and able to provide written informed consent
  • Participants are willing and able to provide appropriate photo identification
  • Participant’s age 18 – 100 years old
  • Participants diagnosed with active non-small cell lung cancer (Adenocarcinoma or Squamous Cell only. All stages are acceptable.)
  • Participants must have associated tissue biomarker data (EFGR and MET mutations) in their medical records

Exclusion Criteria:

  • Participants who are pregnant or nursing
  • Participants with a known history of HIV, hepatitis, or other infectious diseases
  • Participants who have taken an investigational product in the last 30 days
  • Participants who have experienced excess blood loss, including blood donation defined as 250 mL in the last month or 500 mL in the previous two months
  • Participants currently enrolled in a clinical trial
  • Participants currently in remission

Go to 

Layout table for additonal information
Responsible Party: Sanguine Biosciences
ClinicalTrials.gov Identifier: NCT05669105    
Other Study ID Numbers: SAN-08877
First Posted: December 30, 2022    Key Record Dates
Last Update Posted: December 30, 2022
Last Verified: December 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Sanguine Biosciences:

lung cancer
NSCLC

Additional relevant MeSH terms:

Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 1, 2023Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments